Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma

Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer

Alvotech and Dr. Reddy's collaborate on biosimilar candidate to cancer drug pembrolizumab

Aitia partners with Gustave Roussy in identifying fundamental biological causes of human cancers

Innovent's IBI363 granted second breakthrough therapy designation in China

Akeso's cadonilimab gains Chinese approval for first-line treatment of cervical cancer

Zynext Ventures invests in immuno-oncology company Agenus

IGI presents promising full dose-escalation results from Phase 1 study of ISB 2001

ImmuneOncia reports interim results from Phase 1b clinical trial of CD47 antibody

Jazz Pharmaceuticals reports improved survival with Zepzelca (lurbinectedin) and atezolizumab (Tecentriq) combination in extensive-stage small cell lung cancer

Innovent Biologics updates IBI343 data from Phase 1 clinical study in advanced pancreatic cancer

BioNTech and Bristol Myers Squibb partner to co-develop bispecific antibody for solid tumours

Leads Biolabs reports LBL-024 clinical data in advanced EP-NEC at 2025 ASCO

Johnson & Johnson reports first-in-human results for pasritamig in prostate cancer

Taiho Oncology and Cullinan Therapeutics report REZILIENT1 Phase 1/2 data